Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tazemetostat hydrobromide by Ipsen for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma): Likelihood of Approval
Tazemetostat hydrobromide is under clinical development by Ipsen and currently in Phase II for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma). According...
Tazemetostat hydrobromide by Ipsen for Chordoma: Likelihood of Approval
Tazemetostat hydrobromide is under clinical development by Ipsen and currently in Phase II for Chordoma. According to GlobalData, Phase II...
Tazemetostat hydrobromide by Ipsen for Chondrosarcoma: Likelihood of Approval
Tazemetostat hydrobromide is under clinical development by Ipsen and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase II...
Tazemetostat hydrobromide by Ipsen for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Tazemetostat hydrobromide is under clinical development by Ipsen and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...